U.S. Markets open in 8 hrs 9 mins

Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's

Ron Leuty
Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's

The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.